From Wikipedia, the free encyclopedia
Jump to: navigation, search
WikiProject Pharmacology (Rated Start-class, Top-importance)
WikiProject icon This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
Start-Class article Start  This article has been rated as Start-Class on the project's quality scale.
 Top  This article has been rated as Top-importance on the project's importance scale.
WikiProject Medicine / Neurology (Rated Start-class, High-importance)
WikiProject icon This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.
Start-Class article Start  This article has been rated as Start-Class on the project's quality scale.
 High  This article has been rated as High-importance on the project's importance scale.
Taskforce icon
This article is supported by the Neurology task force (marked as High-importance).


Is there an opposite to anti-convulsants ie a medicine that blocks or destroys GABA or by any other way?

1) Not all anticonvulsants are GABA-active. Some of them, yes.
I know that's why I put "or by any other way"
2) Yes, there are compounds, that exhibit GABA-receptor-blockage. Commonly, these substances are (if they penetrate the brain-blood barier) convulsants, or convulsive poisons. Examples are some diene polychlorinated insecticides (dieldrin, endrin, endosulfan and the like) and picrotoxin, as well as other "cage convulsants", like tetramine, for example.--Spiperon 22:01, 23 October 2006 (UTC)

Worth mentioning increased suicide risk with many Anticonvulsants?[edit]

See and

Suggest We mention Lack of Medication Approval[edit]

I think its worth mentioning that MANY anti-seizure DRUGS have never been APPROVED FOR CHILD USE by the (FDA) Food and Drug Administration in the United States.muncher 15:51, 23 October 2006 (UTC)

The licensing situation for children is complex and not unique to anticonvulsants. "One recent estimate was that 75 of the 80 medicines most commonly prescribed for newborns and infants were being prescribed off-label.".[1] Licencing for children often specify several components:

  1. The age, for example: 2, 6, 10 years.
  2. The seizure type, for example: generalised seizures.
  3. The syndrome, for example: Lennox-gastaut syndrome.
  4. Combination, for example: either as monotherapy or in-addition to an established drug (adjunctive usage).

The older drugs such as phenobarbital, ethosuximide and phenytoin are approved for children effectively by default (they were in use well before modern regulations). Here is the FDA approval status of some of the common modern drugs.

  • Topamax (topiramate) Adjundictve treatment of partial seizures (also seizures in Lennox-Gastaut syndrome) in children 2 years and over.[2][3]. Also monotherapy of partial onset or primary generalized tonic-clonic seizures in children 10 years and over. [4]
  • Tegretol (carbamazepine) First-line monotherapy for the treatment of partial, secondarily generalized, and generalized tonic-clonic seizures in children. [5]
  • Trileptal (oxcarbazepine). Adjunctive and monotherapy for the treatment of partial seizures in children 4 years and over. [6][7]
  • Gabitril (tiagabine). Adjunctive treatment of partial seizures in children 12 years and over.[8]
  • Lamictal (lamotrigine). Adjunctive treatment of generalized seizures in Lennox-Gastaut syndrome.[9] Also adjunctive treatment of generalised tonic-clonic seizures in children 2 years and over. [10]
  • Neurontin (gabapentin). Adjunctive treatment of partial seizures in children 3 years and over.[11]
  • Keppra (levetiracetam). Adjuntive treatment of partial seizures in children 4 years and over.[12]
  • Depakote ER (divalproex sodium extended-release). Adjunctive and monotherapy for the treatment of partial seizures in children 10 years and above.[13]

There is a wider choice of licensed drugs for children in the UK.[14] [15].

There remains a shortage of approved medicines for infants (under 2 years). Getting approval for monotherapy is hard, hence adjunctive therapy is established first. If enough off-licence usage is occurring, there is little incentive on the manufacturer to fund trials to widen the licence. What is interesting is that no epilepsy drugs have ever been compared against placebo (largely for ethical reasons) and that, within its indications, no epilepsy drug has ever been shown to be significantly better than any other (older) drug. Some may, however, be better tolerated.[16]

Perhaps some of this information could be added to the article. Colin°Talk 18:40, 23 October 2006 (UTC)

Adding for finding of fact[edit]

Jean P. Davis M.D., and H.H. Ramsey, M.D.

The demonstration of anticonvulsant activity of the tetrahydrocannabinol (THC) cogeners by laboratory tests (Loewe and Goodman, Federation Proc. 6:352, 1947) prompted clinical trial in five institutionalized epileptic children. All of them had symptomatic grand mal epilepsy with retardation; three has cerebral palsy in addition. EEG tracings were grossly abnormal in the entire group; three has focal seizure activity. Their attacks had been inadequately controlled on 0.13 gm. of Phenobarbital daily, combined with 0.3 gm. of Dilantin per day in two of the patients, and in a third, with 0.2 gm. of Mesantoin daily.

Two isomeric 3(1,2-dimethyl heptyl) homologs of THC were tested, numbers 122 and 125A, with ataxia potencies 50 and 8 times, respectively, that of natural Marijuana principles. Number 122 was given to 2 patients for 3 weeks and to 3 patients for 7 weeks. 3 responded at least as well to previous therapy; the 4th became almost completely and the 5th entirely seizure free. One patient transferred to 125A after 3 weeks, had prompt exacerbation of seizures during the ensuing 4 weeks, despite dosages up to 4 mg. daily. The 2nd patient transferred to 125A was adequately controlled on this dosage, except for a brief period of paranoid behavior three and a half weeks later; similar episodes had occurred prior to cannabinol therapy. Other psychic disturbances or toxic reactions were not manifested during the periods of treatment. Blood counts were normal. The cannabinoids herein reported deserve further trial in non-institutionalized epileptics. Reprinted from Federation Proceedings, Federation of American Society for Experimental Biology, vol 8, 1949, p.284.

These proceedings demonstrate unequivocally the Anticonvulsant properties of cannabinods. This is not opinion but fact and is therefore "absolute and non-negotiable" in accordance with WP:NPOV. Adding cannabinoids. Alphaquad 22:05, 19 March 2007 (UTC)

Tetrahydrocannabinol is not professionally used as an anticonvulsant. It (or related compounds) are being researched as such, along with thousands of other chemicals. This article should not mention all drugs that have some anticonvulsant effect - it would be uselessly long. Colin°Talk 22:08, 19 March 2007 (UTC)
Length is not an issue for a single entry. Your persistence shows a biased opinion against this one item and is contrary wiki standards —The preceding unsigned comment was added by Alphaquad (talkcontribs) 22:17, 19 March 2007 (UTC).
Cannabis has well demonstrated anticonvulsant properties; epileptics in Canada have successfully defended their right to use the substance to treat their condition as in the case of Terry Parker. Furthermore, the drug has been used for centuries for this purpose -- its current stigmatized nature in the "Western" medical system does not justify willful ignorance of its effects. Many people are currently using it to successfully treat their condition. It warrants a mention in the article. —Preceding unsigned comment added by (talk) 19:17, 14 September 2009 (UTC)

Approval dates[edit]

Therapeutic drug monitoring in epilepsy by PN Patsalos, NSE. Has a slightly different set of dates for UK drug introductions. Colin°Talk 21:49, 16 November 2007 (UTC)

Suggest adding Lacosamide (Vimpat). EU approval 9/3/08, US approval 10/29/08. — Preceding unsigned comment added by (talk) 14:30, 25 July 2011 (UTC)


I am removing reference [2] and modifiying the sentence that antiepileptics cause cell death. This is wrong and taken out of context. It causes apoptosis in developing neurones, which means the effect is not seen in adult epileptics. I have read the reference and the group were looking at the effects of pregnant women taking AEDs by using postnatal rat models. The information is misleading to the extent that someone is asking about it in Yahoo answers. --Mubinchoudhury (talk) 21:41, 20 May 2008 (UTC)

Proposed eorganisation[edit]

This article is currently most a list, rather than sections with prose. I think there are benefits of having a list of such drugs but also of having an article discussing the drugs in general. Also many modern texts use the term antiepileptic drug (AED) rather than anticonvulsant. So I propose we create two articles:

Any objections? -- Colin°Talk 20:53, 24 February 2013 (UTC)